Scott Byrd, Sudo Biosciences CEO (Frazier Healthcare Partners)
Bristol Myers got the first TYK2 approval. Frazier’s new biotech Sudo hopes to get many more
Earlier in September, the FDA approved a TYK2 inhibitor for the first time, a drug from Bristol Myers Squibb for psoriasis, without slapping on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
